Novo Nordisk shares have seen significant movement recently, rising by 5% despite the company cutting its 2025 sales outlook due to lower-than-expected demand for its obesity drug, Wegovy. The drugmaker reported a first-quarter profit that exceeded forecasts, with sales increasing by 19% in Danish kroner. However, competition from copycat versions of its products and a decline in US prescriptions has put pressure on future sales expectations. Despite these challenges, there are indications of a potential recovery in Wegovy sales, which has led to investor optimism. The company is also preparing for regulatory changes that could impact the market for Wegovy copycats.